Shelly C. Shand, MD
Medical Oncology and Hematology Specialist
Dr. Shand has led clinical research at the forefront of oncology including clinical trial and protocol development in breast cancer, immune therapy, and melanoma. She presented this research at national meetings, including the annual American Society of Clinical Oncology (ASCO) conference, and authored publications and abstracts on these and other topics in hematology and oncology.
Above her interest in clinical research, Dr. Shand’s primary concern is for her patients. By combining exceptional patient care with the most cutting-edge treatments, she will tailor each patient’s plan of care to meet his or her individual needs and concerns. Dr. Shelly Shand is a board-certified physician and a member of the American College of Physicians, American Society of Clinical Oncology, American Society of Hematology, and Alpha Omega Alpha Honor Society. She joined Charleston Oncology in 2018. Dr. Shand is married and enjoys spending time with family, friends, and her two cats. She also enjoys traveling, yoga, and savoring the culinary offerings of Charleston.
Choose your preferred location
Send UsA Message
Dr. Shelly Shand shares important tips for diagnosing breast cancer early and the latest advancements in breast cancer.
Staying Aware for Breast Cancer Awareness monthCharleston Oncology is proud to sponsor Staying Aware for Breast Cancer Awareness month in conjunction with WCIV News Channel 4. We continue to partner with our community to ensure that every woman has the best chance of...
Early-Stage Breast Cancer Characteristics and Treatment OptionsA rise in early-stage breast cancer diagnosis may result from better screening technology and a raised awareness of the importance of annual mammograms. An early-stage breast cancer diagnosis is contained...
Charleston Oncology’s Clinical Trials most recent non–small cell lung cancer trial enrolled the most people in the world. Gene Saylors, MD, oncologist and hematologist at Charleston Oncology, will present the positive findings at the American Association for Cancer Research 2022 Annual Meeting. “When administering a new trial, we are always cautiously optimistic,” says Dr. Gene Saylors. “The positive results of this Neoadjuvant Lung Trial resulted in rapid FDA approval due to its impressive outcomes.”
Clinical trials for a newly-approved cancer treatment for lung cancer in the Lowcountry helped get the drug ready for people around the world, Lowcountry medical officials say.
How should one go about finding the right oncology practice? We interviewed ten Lowcountry breast cancer patients to get their perspectives and advice.